ATNM - A Strong Buy - Actinium Pharmaceuticals Promising AML Treatment With Targeted Radiotherapies
2024-05-12 09:32:38 ET
Summary
- Actinium Pharmaceuticals is a late-stage biopharmaceutical company focused on developing radiotherapies for AML patients.
- The company's leading product candidate, Iomab-B, has shown promising results in clinical trials, increasing survival rates for elderly patients and targeting specific leukemia-related antigens.
- Strategic partnerships, particularly with Immedica AB for the EUMENA market, aim to strengthen Actinium's global market presence.
- I rate ATNM a strong buy due to its innovative AML treatments and promising clinical trial results, despite inherent biotech risks.
...
A Strong Buy - Actinium Pharmaceuticals Promising AML Treatment With Targeted Radiotherapies